Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate

Antiviral Research

Volumn 59, Issue 2, 2003, Pages 89-98

  Bocklandt, Sven ^a   Blumberg, Peter M ^a   Hamer, Dean H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti viral compounds; Human immunodeficiency virus; Immunotoxin; Phorbol ester

Indexed keywords

12 DEOXYPHORBOL 13 PHENYLACETATE; 12 DEOXYPHORBOL DERIVATIVE; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; IMMUNOTOXIN; PHORBOL ESTER DERIVATIVE; PROSTRATIN; PROTEIN KINASE C; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; T LYMPHOCYTE ACTIVATION; VIRUS ACTIVATION; VIRUS EXPRESSION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0041743235     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(03)00034-2     Document Type: Article

References (59)

1. Bartlett J.A., Miralles G.D., Sevin A.D., Silberman M., Pruitt S.K., Ottinger J., Gryszowska V., Fiscus S.A., Bucy R.P. Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. AIDS Res. Hum. Retroviruses. 18:2002;535-543.
2. Blankson J.N., Persaud D., Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53:2002;557-593.
3. Blumberg P.M., Acs G., Areces L.B., Kazanietz M.G., Lewin N.E., Szallasi Z. Protein kinase C in signal transduction and carcinogenesis. Prog. Clin. Biol. Res. 387:1994;3-19.
4. Bogi K., Lorenzo P.S., Szallasi Z., Acs P., Wagner G.S., Blumberg P.M. Differential selectivity of ligands for the C1a and C1b phorbol ester binding domains of protein kinase C delta: possible correlation with tumor-promoting activity. Cancer Res. 58:1998;1423-1428.
5. Cao W., Mattagajasingh S.N., Xu H., Kim K., Fierlbeck W., Deng J., Lowenstein C.J., Ballermann B.J. TIMAP, a novel CAAX box protein regulated by TGF-beta 1 and expressed in endothelial cells. Am. J. Physiol. Cell Physiol. 283:2002;C327-C337.
6. Cashmore A.R., Seelye R.N., Cain B.F., Mack H., Schmidt R.J., Hecker E. The structure of prostratin: a toxic teracyclic dipterene ester from Pimela prostrata. Tet. Lett. 20:1976;1737-1738.
7. Chew C.S., Parente J.A. Jr., Chen X., Chaponnier C., Cameron R.S. The LIM and SH3 domain-containing protein, lasp-1, may link the cAMP signaling pathway with dynamic membrane restructuring activities in ion transporting epithelia. J. Cell Sci. 113(Pt. 11):2000;2035-2045.
8. Chun T.W., Fauci A.S. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. U.S.A. 96:1999;10958-10961.
9. Chun T.W., Engel D., Mizell S.B., Ehler L.A., Fauci A.S. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J. Exp. Med. 188:1998;83-91.
10. Chun T.-W., Engel D., Mizell S.B., Hallahan C.W., Fischette M., Park S., Davey R.T. Jr., Dybul M., Kovacs J.A., Metcalf J.A., Mican J.M., Berrey M.M., Corey L., Lane H.C., Fauci A.S. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5:1999;651-655.
11. Clamp A., Jayson G. The clinical development of the bryostatins. Anticancer Drugs. 13:2002;673-683.
12. Clouse K.A., Powell D., Washington I., Poli G., Strebel K., Farrar W., Barstad P., Kovacs J., Fauci A.S., Folks T.M. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J. Immunol. 142:1989;431-438.
13. Cobb M.H., Hepler J.E., Cheng M., Robbins D. The mitogen-activated protein kinases, ERK1 and ERK2. Semin. Cancer Biol. 5:1994;261-268.
14. Dybul M., Hidalgo B., Chun T.W., Belson M., Migueles S.A., Justement J.S., Herpin B., Perry C., Hallahan C.W., Davey R.T., Metcalf J.A., Connors M., Fauci A.S. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J. Infect. Dis. 185:2002;61-68.
15. Eisen M.B., Brown P.O. DNA arrays for analysis of gene expression. Methods Enzymol. 303:1999;179-205.
16. Evans F.J., Schmidt R.J. The succulent euphorbias of Nigeria. III. Structure and potency of the aromatic ester diterpenes of Euphorbia poissonii Pax. Acta Pharmacol. Toxicol. (Copenhagen). 45:1979;181-191.
17. Fichter M., Hinrichs R., Eissner G., Scheffer B., Classen S., Ueffing M. Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C. Oncogene. 14:1997;2817-2824.
18. Folks T.M., Clouse K.A., Justement J., Rabson A., Duh E., Kehrl J.H., Fauci A.S. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T cell clone. Proc. Natl. Acad. Sci. U.S.A. 86:1989;2365-2368.
19. Fraser C., Ferguson N.M., Ghani A.C., Prins J.M., Lange J.M., Goudsmit J., Anderson R.M., de Wolf F. Reduction of the HIV-1-infected T cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS. 14:2000;659-669.
20. Gulakowski R.J., McMahon J.B., Buckheit R.W. Jr., Gustafson K.R., Boyd M.R. Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res. 33:1997;87-97.
21. Gustafson K.R., Cardellina J.H. II, McMahon J.B., Gulakowski R.J., Ishitoya J., Szallasi Z., Lewin N.E., Blumberg P.M., Weislow O.S., Beutler J.A.et al. A nonpromoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J. Med. Chem. 35:1992;1978-1986.
22. Han X.M., Laras A., Rounseville M.P., Kumar A., Shank P.R. Human immunodeficiency virus type 1 Tat-mediated trans activation correlates with the phosphorylation state of a cellular TAR RNA stem-binding factor. J. Virol. 66:1992;4065-4072.
23. Hergenhahn M., Kusumoto S., Hecker E. On the active principles of the spurge family (Euphorbiaceae). V. Extremely skin-irritant and moderately tumor-promoting diterpene esters from Euphorbia resinifera Berg. J. Cancer Res. Clin. Oncol. 108:1984;98-109.
24. Hirota T., Morisaki T., Nishiyama Y., Marumoto T., Tada K., Hara T., Masuko N., Inagaki M., Hatakeyama K., Saya H. Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with h-warts/LATS1 tumor suppressor. J. Cell Biol. 149:2000;1073-1086.
25. Ho D.D. Toward HIV eradication or remission: the tasks ahead. Science. 280:1998;1866-1867.
26. Jakobovits A., Rosenthal A., Capon D.J. Trans-activation of HIV-1 LTR-directed gene expression by tat requires protein kinase C. EMBO J. 9:1990;1165-1170.
27. Kagnoff M.F., Roebuck K.A. Human immunodeficiency virus type 1 (HIV-1) infection and expression in intestinal epithelial cells: role of protein kinase A and C pathways in HIV-1 transcription. J. Infect. Dis. 179(Suppl. 3):1999;S444-S447.
28. Kalams S.A., Goulder P.J., Shea A.K., Jones N.G., Trocha A.K., Ogg G.S., Walker B.D. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73:1999;6721-6728.
29. Kanashiro C.A., Khalil R.A. Signal transduction by protein kinase C in mammalian cells. Clin. Exp. Pharmacol. Physiol. 25:1998;974-985.
30. Kelso A., Costelloe E.O., Johnson B.J., Groves P., Buttigieg K., Fitzpatrick D.R. The genes for perforin, granzymes A-C and IFN-gamma are differentially expressed in single CD8(+) T cells during primary activation. Int. Immunol. 14:2002;605-613.
31. Kim C.H., Lim S.J., Gollapudi S., Gupta S. Role of protein kinase C isozymes in activation of human immunodeficiency virus type 1 in chronically infected promonocytic cells: evidence against a role of PKC beta 1. Biochem. Biophys. Res. Commun. 199:1994;292-297.
32. Kirchner J., Bevan M.J. ITM2A is induced during thymocyte selection and T cell activation and causes downregulation of CD8 when overexpressed in CD4(+)CD8(+) double positive thymocytes. J. Exp. Med. 190:1999;217-228.
33. Korin Y.D., Brooks D.G., Brown S., Korotzer A., Zack J.A. Effects of prostratin on T cell activation and human immunodeficiency virus latency. J. Virol. 76:2002;8118-8123.
34. Kulkosky J., Culnan D.M., Roman J., Dornadula G., Schnell M., Boyd M.R., Pomerantz R.J. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood. 98:2001;3006-3015.
35. Lee E.G., Boone D.L., Chai S., Libby S.L., Chien M., Lodolce J.P., Ma A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 289:2000;2350-2354.
36. Legg J.W., Lewis C.A., Parsons M., Ng T., Isacke C.M. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat. Cell Biol. 4:2002;399-407.
37. Marquez V.E., Nacro K., Benzaria S., Lee J., Sharma R., Teng K., Milne G.W., Bienfait B., Wang S., Lewin N.E., Blumberg P.M. The transition from a pharmacophore-guided approach to a receptor-guided approach in the design of potent protein kinase C ligands. Pharmacol. Ther. 82:1999;251-261.
38. Martinez-Picado J., Morales-Lopetegi K., Wrin T., Prado J.G., Frost S.D., Petropoulos C.J., Clotet B., Ruiz L. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS. 16:2002;895-899.
39. Matsuda S., Rouault J., Magaud J., Berthet C. In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett. 497:2001;67-72.
40. McHugh, L., Hu, S., Lee, B.K., Santora, K., Kennedy, P.E., Berger, E.A., Pastan, I., Hamer, D.H., 2002. Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis. J. Biol. Chem.
41. Nabel G., Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 326:1987;711-713.
42. Nicoll S.B., Barak O., Csoka A.B., Bhatnagar R.S., Stern R. Hyaluronidases and CD44 undergo differential modulation during chondrogenesis. Biochem. Biophys. Res. Commun. 292:2002;819-825.
43. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 9:1995;484-496.
44. Ogg G.S., Jin X., Bonhoeffer S., Moss P., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Hurley A., Markowitz M., Ho D.D., McMichael A.J., Nixon D.F. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73:1999;797-800.
45. Pomerantz R.J. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin. Infect. Dis. 34:2002;91-97.
46. Prins J.M., Jurriaans S., van Praag R.M., Blaak H., van Rij R., Schellekens P.T., Ten Berge I.J., Yong S.L., Fox C.H., Roos M.T., de Wolf F., Goudsmit J., Schuitemaker H., Lange J.M. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS. 13:1999;2405-2410.
47. Rabinovich G.A., Baum L.G., Tinari N., Paganelli R., Natoli C., Liu F.T., Iacobelli S. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 23:2002;313-320.
48. Roebuck K.A., Gu D.S., Kagnoff M.F. Activating protein-1 cooperates with phorbol ester activation signals to increase HIV-1 expression. AIDS. 10:1996;819-826.
49. Rosenberg Z.F., Fauci A.S. Immunopathogenic mechanisms of HIV infection. Clin. Immunol. Immunopathol. 50:1989;S149-S156.
50. Schmidt R.J., Evans F.J. Skin irritant effects of esters of phorbol and related polyols. Arch. Toxicol. 44:1980;279-289.
51. Seimiya M., J O.W., Bahar R., Kawamura K., Wang Y., Saisho H., Tagawa M. Stage-specific expression of Clast6/E3/LAPTM5 during B cell differentiation: elevated expression in human B lymphomas. Int. J. Oncol. 22:2003;301-304.
52. Sonza S., Crowe S.M. Reservoirs for HIV infection and their persistence in the face of undetectable viral load. AIDS Patient Care STDS. 15:2001;511-518.
53. Strair R.K., Schaar D., Goodell L., Aisner J., Chin K.V., Eid J., Senzon R., Cui X.X., Han Z.T., Knox B., Rabson A.B., Chang R., Conney A. Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin. Cancer Res. 8:2002;2512-2518.
54. Szallasi Z., Krausz K.W., Blumberg P.M. Non-promoting 12-deoxyphorbol 13-esters as potent inhibitors of phorbol 12-myristate 13-acetate-induced acute and chronic biological responses in CD-1 mouse skin. Carcinogenesis. 13:1992;2161-2167.
55. Szallasi Z., Krsmanovic L., Blumberg P.M. Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. Cancer Res. 53:1993;2507-2512.
56. van Praag R.M., Prins J.M., Roos M.T., Schellekens P.T., Ten Berge I.J., Yong S.L., Schuitemaker H., Eerenberg A.J., Jurriaans S., de Wolf F., Fox C.H., Goudsmit J., Miedema F., Lange J.M. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J. Clin. Immunol. 21:2001;218-226.
57. Williamson E.M., Westwick J., Kakkar V.V., Evans F.J. Studies on the mechanism of action of 12-deoxyphorbolphenylacetate, a potent platelet aggregating tigliane ester. Biochem. Pharmacol. 30:1981;2691-2696.
58. Yang X., Chen Y., Gabuzda D. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaB. J. Biol. Chem. 274:1999;27981-27988.
59. Zhang G., Kazanietz M.G., Blumberg P.M., Hurley J.H. Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester. Cell. 81:1995;917-924.